BioInvent to Showcase BI-1206 and BI-1808 Hematology Progress at June KOL Event
LUND, Sweden, June 1, 2026 BioInvent International AB announced that it will host a key opinion leader (KOL) event...
Cancer Immunotherapy
Advertisement
PeproMene Bio CAR-T Therapy Shows Durable Lymphoma Responses
IRVINE, California, May 29, 2026 PeproMene Bio, Inc. has announced that updated clinical data from its ongoing Phase 1...
OS Therapies Advances OST-HER2 Ahead of ASCO 2026 Presentation
NEW YORK and ROCKVILLE, Md., May 29, 2026 OS Therapies announced the publication of four scientific articles focused on...
Enterome Wins FDA Orphan Tag for EO2463 in iNHL
Paris, France | May 28, 2026 Enterome announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to...
Trogenix Doses First Patient in TGX-007 Glioblastoma Trial
Edinburgh, UK | May 28, 2026 Clinical-stage oncology company Trogenix announced the first patient has been dosed in the...
Advertisements
Virax Biolabs Reports Positive Long COVID Data
LONDON, United Kingdom, May 26, 2026 Virax Biolabs Group Limited has announced encouraging early clinical data for ViraxImmune™, its...
Citius Oncology LYMPHIR ASCO Phase 1 Data
CRANFORD, New Jersey, May 26, 2026 Citius Oncology, Inc. has announced that new Phase 1 clinical study data evaluating...
Adcendo and MSD Expand KEYTRUDA Cancer Trial
COPENHAGEN, Denmark, May 26, 2026 Adcendo ApS has announced a new clinical collaboration and supply agreement with MSD (Merck...
Oncolytics’ Pelareorep Shows Strong KRAS-Targeted Immune Activation at ASCO 2026
SAN DIEGO, May 22, 2026 Oncolytics Biotech® announced new translational data from its GOBLET and AWARE-1 studies showing that...
Mestag Therapeutics Doses First Patient in STARLYS Trial of MST-0312 for Solid Tumors
CAMBRIDGE, UK, May 19, 2026 Mestag Therapeutics announced the first patient has been dosed in the Phase 1 STARLYS...
Advertisement
